Benzinga | Jul 20, 2021 07:07AM EDT

RedHill Biopharma Reports Extension Of Unrestricted Commercial Coverage For Talicia With OptumRx

Addition of Talicia(r) by OptumRx significantly extends Commercial patient access to Talicia(r) through this leader in U.S. healthcare

Patient access to Talicia now extends to greater than 8 out of 10 covered U.S. Commercial lives

Talicia(r) is the first and only FDA-approved rifabutin-based therapy for H. pylori infection, designed as a first-line option to address the high resistance of H. pylori bacteria to standard-of-care therapies

H. pylori bacterial infection is a Group 1 carcinogen and the strongest risk factor for gastric cancer; H. pylori affects approximately 35% of the U.S. population

TEL-AVIV, Israel and RALEIGH, N.C., July 20, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that OptumRx, part of the UnitedHealth Group - a leader in healthcare coverage, partnered with more than 1.3 million healthcare professionals and 6,500 hospitals, has added Talicia(r) (omeprazole magnesium, amoxicillin and rifabutin)[1] to its Commercial Formulary as an unrestricted brand for H. pylori treatment, effective July 1, 2021.





"Momentum with Talicia is growing strongly and the addition of unrestricted Commercial coverage for Talicia by OptumRx, a major operator in U.S. healthcare coverage serving more than 26 million Americans, is an important advance in extending patient access to Talicia, which now extends to greater than 8 out of 10 covered U.S. Commercial lives," said Rick Scruggs, RedHill's Chief Commercial Officer. "Talicia is the first and only FDA-approved rifabutin-based therapy for the treatment of H. pylori infection, and this listing represents the understanding within the medical community of the need to combat the high and growing resistance of H. pylori to commonly used antibiotics with an effective new first-line treatment."